Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

5-Year Results of Dabrafenib Plus Trametinib Treatment in Metastatic Melanoma Demonstrate the Benefits of Targeted Drugs

5-Year Results of Dabrafenib Plus Trametinib Treatment in Metastatic Melanoma Demonstrate the Benefits of Targeted Drugs

Historically, metastatic (stage 4) melanoma has been associated with a poor prognosis (disease course) and relatively short survival, but treatments targeting BRAF and MEK mutations and the use of immune checkpoint inhibitorshave significantly improved outcomes in these patients. However, many patients develop drug resistance (primary or acquired), ultimately resulting in death from the underlying disease.

Malignant melanoma accounts for approximately %5 of skin cancers and has aggressive cancer biology. Genetic research has shown that melanomas fall into two main groups: BRAF mutation-positive and BRAF mutation-negative.

To Summarize the Results of New-Generation Treatments Used in Advanced Melanoma;

Among previously untreated patients with advanced melanoma, in phase-3 clinical studies, those receiving anti-PD-1 immunotherapies (pembrolizumab or nivolumab) had 4-year progression-free survival rates of % 27 to 31 and an overall survival rate of % 46; among patients receiving pembrolizumab, the 5-year overall survival rate was % 43. The combination of nivolumab plus ipilimumab produced, in treated patients, 4-year progression-free and overall survival rates of % 37 and % 53, respectively. However, to date, phase 3 clinical trials of other BRAF-targeted treatments apart from immunotherapy have not reported 5-year survival data. These data will be critical for evaluating the potential of treatment to provide long-term disease control and understanding factors predicting long-term survival.

Note: The BRAF inhibitor dabrafenib (Tafinlar) plus the MEK inhibitor trametinib (Mekinist) received FDA approval on 9 January 2014 for treating advanced, BRAF mutation-positive melanoma. The same combination later received approval on 30 April 2018 for postoperative treatment in stage 3 melanoma as adjuvant (protective) therapy from the FDA.

Two previously reported phase 3 clinical trials (COMBI-d and COMBI-v), compared with BRAF inhibitor monotherapy, in patients with metastatic melanoma carrying BRAF V600E or V600K mutations, evaluated dabrafenib plus trametinibfor efficacy and safety. In an earlier analysis of patients treated with dabrafenib plus trametinib in COMBI-d and COMBI-v, 3-year progression-free and overall survival rates were % 23 and % 44, respectively. Univariate and multivariate analyses showed significant associations between several baseline factors (such as general performance status, age, sex, number of metastatic organ sites and lactate dehydrogenase level) and both progression-free and overall survival.

Findings of a 5-year analysis of melanoma patients treated with dabrafenib plus trametinib in COMBI-d and COMBI-v, including progression-free and overall survival, were reported on 15 August 2019 in NEJM the journal. An analysis of factors appearing to be associated with patients who derived long-term benefit from this treatment was also presented.

Details of the Analyses

The COMBI-d and COMBI-v clinical trials included previously untreated patients receiving the BRAF inhibitor dabrafenib (150 mg twice daily) and the MEK inhibitor trametinib (2 mg once daily). Median follow-up in the studies was 22 months (range 0 - 76). The primary endpoints in COMBI-d and COMBI-v were progression-free survival and overall survival, respectively.

Results:

  • A total of 563 patients were randomly assigned to receive dabrafenib plus trametinib (211 patients in COMBI-d and 352 in COMBI-v).
  • Progression-free survival rates at 4 years were % 21 and at 5 years % 19.
  • Overall survival rates at 4 years were % 37 and at 5 years % 34. Thus, in an advanced cancer with such aggressive biology, of every 3 melanoma patients, 1 had a lifespan of at least 5 years.
  • In multivariate data analysis, several baseline factors (such as performance status, age, sex, number of metastatic organ sites and lactate dehydrogenase level) were found to be significantly associated with both progression-free and overall survival.
  • Complete response occurred in 109 patients (% 19), and achieving a complete response resulted in better long-term survival; in this patient group, the 5-year overall survival rate was % 71.

The study's most striking finding was that, in advanced BRAF V600E or V600K mutation-positive melanoma, first-line treatment with dabrafenib plus trametinib provided long-term benefit in approximately one-third of patients.

Sources

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

5-Year Results of Dabrafenib Plus Trametinib Treatment in Metastatic Melanoma Demonstrate the Benefits of Targeted Drugs

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy